Researchers sought to evaluate differences in ctDNA profiles, use of targeted treatments, and overall survival between Black and White patients with metastatic breast cancer.

With the realization that the gross genetic abnormalities that activated MYC in cancer universally led to deregulated expression of the intact coding region, a series of new questions arose.

Indeed, expressing MYC at high levels can trigger DNA damage, forcing cancer cells to carefully balance the costs and benefits of ecDNA retention. "That was unexpected," says Corbo.

ACB’s expertise in synthetic lethal approaches to precision oncology, MYC biology and cancer cell biology has enabled it to build a broad pipeline. Rather than focus on a single asset or one ...

Importantly, we also discovered that certain mutations, like MYC, appear early in prostate cancer development and are linked to more aggressive forms of the disease. "If these mutations occur in ...

Neuroblastomas are the most common cancer in infants, with about 700–800 diagnoses per year in the US, according to the American Cancer Society. Some of the most high-risk cases are driven by elevated ...

AUTX-703, a novel and potent oral KAT2A and KAT2B protein degrader, inhibits growth and induces profound, persistent cell state differentiation in SCLC modelsNEWTON, Mass., April 03, 2025 (GLOBE ...

Dewpoint will present two posters at AACRCondensate modulators (c-mods) demonstrate robust anti-tumor effects across multiple types of ...

which cause therapeutic vulnerabilities in breast cancer. Our current research specifically focuses on therapeutic strategies aiming to exploit MYC oncogene-induced vulnerabilities and therapeutically ...